Cellectar Biosciences, Inc. (CLRB) Balance Sheet

22Y historyFree accessUpdated daily

The firm's financial position appears increasingly vulnerable as total assets contracted from $42.9 million in 2024Q1 to $11.1 million in 2026Q1, while accumulated deficits reached $274.8 million.

Annual statement

CLRB Balance Sheet

Cellectar Biosciences, Inc. (CLRB) balance sheet — 22-year assets, liabilities & shareholders' equity history

Annual Quarterly

Metric	TTM	Dec'25	Dec'24	Dec'23	Dec'22	Dec'21	Dec'20	Dec'19	Dec'18	Dec'17	Dec'16	Dec'15	Dec'14	Dec'13	Dec'12	Dec'11	Dec'10	Dec'09	Dec'08	Dec'07	Dec'06	Dec'05	Dec'04

Total Current Assets	34.88M	14.04M	24.25M	10.45M	20.53M	36.57M	57.94M	11.39M	13.95M	10.47M	12.19M	4.18M	9.7M	2.77M	5.13M	5.82M	2.44M	8.87M	1.39M	11.06M	11.89M	4.8M	102.57K
Cash & Short-Term Investments	33.99M	13.2M	23.29M	9.56M	19.87M	35.7M	57.17M	10.61M	13.26M	10.01M	11.44M	3.86M	9.42M	2.42M	4.68M	5.51M	2.37M	8.77M	1.26M	9.74M	9.94M	4.27M	10.36K
Cash Only	33.99M	13.2M	23.29M	9.56M	19.87M	35.7M	57.17M	10.61M	13.26M	10.01M	11.44M	3.86M	9.42M	2.42M	4.68M	5.51M	2.37M	8.77M	1.26M	9.74M	9.94M	4.27M	10.36K
Short-Term Investments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	12.58K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	925.67
Inventory	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	842.43K	961.66K	888.23K	663.24K	0	0	0	55K	55K	55K	55K	55K	55K	125.54K	55K	555K	0	0	1.18M	1.66M	196.91K	79.63K
Total Non-Current Assets	1.76M	939.86K	1.22M	1.62M	1.06M	630.35K	719.56K	865.14K	1.1M	1.93M	3.13M	3.42M	3.72M	4.05M	6.35M	4.75M	24.11K	59.45K	73.8K	48.16K	34.69K	136.77K	6K
Property, Plant & Equipment	1.74M	910.08K	1.19M	1.59M	978.98K	549.13K	638.35K	783.92K	543.34K	244.71K	1.44M	1.73M	2.03M	2.36M	2.65M	3.04M	8.76K	44.1K	58.45K	32.81K	23.81K	22.61K	0
Fixed Asset Turnover	0.00x	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.00x	3.81x	2.18x	2.16x	-	-	0.56x	-
Goodwill	0	0	0	0	0	0	0	0	0	1.68M	1.68M	1.68M	1.68M	1.68M	1.68M	1.68M	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	15.35K	15.35K	0	0	0	0	0
Other Non-Current Assets	23.57K	29.78K	29.78K	29.78K	81.21K	81.21K	81.21K	81.21K	558.91K	11.87K	11.87K	11.87K	11.87K	11.87K	2.03M	27.22K	0	0	15.35K	15.35K	10.88K	114.16K	6K
Total Assets	36.64M	14.98M	25.47M	12.08M	21.59M	37.2M	58.66M	12.25M	15.05M	12.87M	15.32M	7.6M	13.42M	6.82M	11.48M	10.56M	2.46M	8.93M	1.47M	11.11M	11.92M	4.94M	108.57K
Asset Turnover	0.00x	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.00x	0.01x	0.01x	0.09x	-	-	0.00x	0.05x
Asset Growth %	34.87%	-41.2%	110.96%	-44.07%	-41.97%	-36.58%	378.82%	-18.62%	16.96%	-16.01%	101.74%	-43.39%	96.88%	-40.62%	8.66%	329.3%	-72.45%	509.25%	-86.8%	-6.84%	141.43%	4448.82%	-
Total Current Liabilities	5.24M	4.75M	9.39M	25.36M	11.5M	3.99M	3.56M	2.77M	1.62M	2.11M	1.63M	5.7M	6.23M	4.52M	732.69K	503.58K	904.82K	16.97M	6.62M	7.06M	1.31M	217.16K	4.44M
Accounts Payable	5.22M	1.44M	4.11M	5.62M	2.56M	1.42M	1.43M	1.28M	1.54M	1.87M	1.42M	0	0	1.16M	716.99K	478.04K	565.72K	3.3M	4.65M	6.37M	1.09M	211.46K	2.03M
Days Payables Outstanding	-12.77K	2.46K	-	-	-	-	-	2.46K	6.85K	440.95	1.45K	-	-	-	-	-	-	-	-	-	-	-	291.43K
Short-Term Debt	0	0	0	0	0	0	0	0	0	0	86.59K	243.59K	119.92K	0	0	0	204.8K	0	0	0	0	0	2.02M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	33.33K	0	0	0	0	0
Other Current Liabilities	17K	1.32M	4.59M	17.61M	7.98M	1.94M	0	990.87K	76.09K	243.99K	127.13K	5.46M	2.06M	0	13.3K	23.3K	321.58K	10.49M	1.72M	0	0	5.7K	397.61K
Current Ratio	6.66x	2.96x	2.58x	0.41x	1.78x	9.16x	16.26x	4.11x	8.60x	4.95x	7.47x	0.73x	1.56x	0.61x	7.00x	11.55x	2.69x	0.52x	0.21x	1.57x	9.05x	22.11x	0.02x
Quick Ratio	6.66x	2.96x	2.58x	0.41x	1.78x	9.16x	16.26x	4.11x	8.60x	4.95x	7.47x	0.73x	1.56x	0.61x	7.00x	11.55x	2.69x	0.52x	0.21x	1.57x	9.05x	22.11x	0.02x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities	1.53M	309.4K	1.79M	494K	552.98K	166.29K	301.74K	421.64K	171K	2.21K	151.83K	243.53K	488.98K	593.23K	587.1K	578.47K	366.67K	18.86M	433.33K	9.92M	0	0	13.73K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0	0	86.63K	330.08K	450K	450K	450K	0	0	0	0	0	0	0
Capital Lease Obligations	3.7M	309.4K	409.59K	494K	552.98K	166.29K	301.74K	421.64K	0	2.21K	5.25K	7.97K	11.13K	0	1.69K	4.09K	6.33K	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-124.38K	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	1.38M	0	0	0	0	0	171K	0	146.58K	148.92K	147.77K	143.23K	135.4K	0	-6.33K	18.46M	0	9.92M	0	0	1.14K
Total Liabilities	6.77M	5.06M	11.18M	25.85M	12.05M	4.16M	3.86M	3.19M	1.79M	2.12M	1.78M	5.95M	2.67M	5.12M	1.32M	1.08M	1.25M	35.83M	7.05M	16.98M	1.31M	217.16K	4.46M
Total Debt	1.53M	409.59K	494K	552.98K	603.83K	301.74K	421.64K	527.53K	2.21K	5.25K	94.57K	340.65K	463.31K	451.69K	454.09K	456.33K	0	0	0	0	0	0	2.02M
Net Debt	-32.46M	-12.79M	-22.79M	-9.01M	-19.26M	-35.4M	-56.74M	-10.09M	-13.25M	-10M	-11.35M	-3.52M	-8.96M	-1.97M	-4.22M	-5.05M	-2.37M	-8.77M	-1.26M	-9.74M	-9.94M	-4.27M	2.01M
Debt / Equity	0.05x	0.04x	0.03x	-	0.06x	0.01x	0.01x	0.06x	0.00x	0.00x	0.01x	0.21x	0.04x	0.27x	0.04x	0.05x	-	-	-	-	-	-	-
Debt / EBITDA	-0.07x	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	1.39x	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-445.95x	-819.09x	-1196.63x	-10171.50x	-21.66x	-1209.34x	-941.47x	-16.07x	-	-	-	-	-	-	-2.91x
Total Equity	29.87M	9.92M	14.29M	-13.78M	9.54M	33.05M	54.79M	9.06M	13.26M	10.75M	13.54M	1.65M	10.75M	1.7M	10.16M	9.48M	1.21M	-26.9M	-5.58M	-5.87M	10.61M	4.72M	-4.35M
Equity Growth %	188.44%	-30.61%	203.76%	-244.48%	-71.14%	-39.69%	504.84%	-31.68%	23.31%	-20.57%	720.7%	-84.65%	532.28%	-83.27%	7.14%	685.77%	104.49%	-381.61%	4.87%	-155.33%	124.71%	208.57%	-
Book Value per Share	2.44	3.80	11.55	-33.82	40.54	178.57	829.69	354.12	1343.15	2299.44	9305.75	6329.37	70194.33	18244.93	148221.21	237433.61	-	-	-	-	-	-	-962872.70
Total Shareholders' Equity	29.87M	9.92M	14.29M	-13.78M	9.54M	33.05M	54.79M	9.06M	13.26M	10.75M	13.54M	1.65M	10.75M	1.7M	10.16M	9.48M	1.21M	-26.9M	-5.58M	-5.87M	10.61M	4.72M	-4.35M
Common Stock	83	42	461	207	94	611	454	94	47	167	104	9	76	574	464	369	4.53K	697	440	392	392	279	44
Retained Earnings	-281.72M	-269.13M	-247.34M	-202.76M	-159.99M	-150.9M	-126.78M	-111.68M	-97.59M	-84.35M	-70.79M	-64.61M	-59.17M	-51.06M	-40.28M	-31.48M	-73.98M	-76.07M	-59.69M	-43.24M	-23.68M	-15.4M	-12.35M
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-1.96K
Accumulated OCI	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-2.46M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Key Metrics

Growth RegimeMixed

ProfitabilityNegative

Balance SheetVulnerable

Cash FlowBurning

Top Statement Risk

Capital structure dilution risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Asset Base Contraction Signals Urgency

As reported in recent financial filings, Cellectar's total assets have declined from a peak of $42.9 million in 2024Q1 to $11.1 million in 2026Q1, reflecting a rapid consumption of resources to fund clinical development without a corresponding replenishment from commercial revenue streams.

The consistent downward trend in total assets suggests that the company is operating in a capital-constrained environment where liquidity is prioritized for trial execution over balance sheet expansion. Investors should monitor whether this trajectory necessitates further dilutive financing to maintain the current clinical development pace.

Cash Runway Nears Critical Threshold

Based on the most recent quarterly data, Cellectar's cash position has dwindled to $8.3 million as of 2026Q1, a significant reduction from the $40.0 million reported in 2024Q1, which underscores the company's ongoing reliance on external capital to sustain its research-heavy operational model.

While the current ratio of 1.90 suggests a temporary ability to cover short-term obligations, the absolute cash level appears insufficient for long-term clinical and commercialization requirements. This liquidity profile indicates that the company remains highly sensitive to capital market conditions and potential financing delays.

Equity Erosion Reflects Persistent Losses

According to historical balance sheet data, the company's equity base has been severely impacted by accumulated deficits, which reached $274.8 million by 2026Q1, highlighting the substantial capital destruction inherent in the firm's long-term pursuit of its proprietary PDC platform.

The erosion of equity, punctuated by a negative equity position in 2023Q4, suggests that the company's survival is heavily dependent on periodic equity issuances. This pattern of dilution warrants close investigation by investors, as it directly impacts the potential for future per-share value creation.

Hidden Risks in Capital Structure

As indicated by the company's financial disclosures, the presence of $1.5 million in total debt as of 2026Q1, while modest, introduces a layer of fixed obligations that complicates the firm's already precarious liquidity position during this critical pre-commercial phase of development.

Although the debt-to-equity ratio of 0.32 appears manageable, the lack of recurring revenue means that even minor debt service requirements could exacerbate the existing cash burn. Investors should remain cautious regarding the potential for restrictive covenants or further dilution if the company seeks to restructure these obligations.

CLRB — Frequently Asked Questions

Quick answers to the most common questions about buying CLRB stock.

What are the total assets of Cellectar Biosciences, Inc. (CLRB)?

As of 2025, Cellectar Biosciences, Inc. (CLRB) had total assets of $15.0M including $14.0M in current assets.

How much debt does Cellectar Biosciences, Inc. (CLRB) have?

Cellectar Biosciences, Inc. (CLRB) carries total debt of $0.4M, offset by $13.2M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Cellectar Biosciences, Inc.?

Cellectar Biosciences, Inc. (CLRB) has total shareholders' equity (book value) of $9.9M ($3.80 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Cellectar Biosciences, Inc.'s current ratio and liquidity?

Cellectar Biosciences, Inc. (CLRB) reported a current ratio of 2.96x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.